Literature DB >> 1560924

Treatment of extensively invasive (giant) prolactinomas with bromocriptine.

S K Grebe1, J W Delahunt, C M Feek.   

Abstract

We report four cases of extensively invasive giant prolactinomas. No tumour was suitable for total or near total resection because of invasion into surrounding bone. All had undergone radiotherapy prior to dopamine agonist therapy. Prolactin levels were between 103,000 mlU/L and 1,700,000 mlU/L at presentation, but all tumours responded to bromocriptine therapy and prolactin levels fell into the normal range in three patients within two to 24 months. The fourth patient's level fell to just above the reference range (700 mlU/L) within 36 months. None of the patients has died of their pituitary tumour or related complications to date. Giant prolactinomas appear to be exquisitely sensitive to treatment with bromocriptine. The role of radiotherapy is unclear, but it might contribute to long term control. Surgery should be limited to control of local complications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560924

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  9 in total

1.  Combined treatment of invasive giant prolactinomas.

Authors:  Chonjiang Yu; Zhebao Wu; Jian Gong
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.

Authors:  J Berwaerts; J Verhelst; R Abs; B Appel; C Mahler
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

Review 4.  How to investigate and treat: headache and hyperprolactinemia.

Authors:  Gennaro Bussone; Susanna Usai; Franca Moschiano
Journal:  Curr Pain Headache Rep       Date:  2012-08

5.  Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.

Authors:  Susana Mascarell; David H Sarne
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 6.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

7.  Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.

Authors:  Ilan Shimon; Ernesto Sosa; Victoria Mendoza; Yona Greenman; Amit Tirosh; Etual Espinosa; Vera Popovic; Andrea Glezer; Marcello D Bronstein; Moises Mercado
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

8.  Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population.

Authors:  Farida Chentli; Said Azzoug; Katia Daffeur; Lina Akkache; Hadjer Zellagui; Meriem Haddad; Nadia Kalafate
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

9.  Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma.

Authors:  J K Prague; C L Ward; O G Mustafa; B C Whitelaw; A King; N W Thomas; J Gilbert
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.